Background: Chronic Lymphocytic Leukaemia (CLL) is an indolent disorder, which mainly affects
older adults. Since the advent of chemoimmunotherapy, great progress has been made in its treatment. However,
some patients develop a more aggressive form of the disease and are included in the group of high-risk CLL
patients with a dismal prognosis and a need for new therapies.
Objective: Maltotriose-modified poly(propylene imine) dendrimers were presented as potential agents in targeted
therapy for CLL in the murine xenograft model.
Methods: Tumour, brain and internal organs resected from NOD scid gamma mice were subjected to gross and
Results: The results of ex vivo tissue examination indicated that open-shell glycodendrimers prevented/inhibited
the spread of CLL into the brain and internal organs and its transformation into a more aggressive form.
Conclusion: The results of the study have a potentially important impact on the design of future personalized
therapies as well as clinical trials.